BGM Group (BGM) vs Inovio Pharmaceuticals (INO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Inovio Pharmaceuticals (INO) has outperformed BGM Group (BGM) over the past year, losing 57.4% versus a loss of 96.6%. Over five years, BGM leads with a -98.3% price change compared with -98.7% for INO. BGM Group is the larger company by market cap ($143.6 million vs $118.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BGM | INO |
|---|---|---|
| Share price | $10.75 | $1.15 |
| Market cap | $143.56M | $118.91M |
| 1-day change | +10.94% | +5.50% |
| YTD return | -91.00% | -37.36% |
| 1-year return | -96.64% | -57.42% |
| 5-year return | -98.32% | -98.71% |
| EPS (TTM) | $-4.80 | $-0.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $303.00 | $2.72 |
| 52-week low | $6.45 | $0.56 |
| Distance from 52-week high | -96.45% | -57.72% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +175.65% |
| Average volume | 6.09K | 3.86M |
| Shares outstanding | 12.69M | 103.40M |
| Employees | — | 112 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INO has outperformed BGM by 39.2 percentage points over the past year.
About BGM Group
BGM stock →BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.
Health Care · Biotechnology: Pharmaceutical Preparations
About Inovio Pharmaceuticals
INO stock →Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
BGM vs INO FAQ
Which is bigger, BGM Group or Inovio Pharmaceuticals?
BGM Group (BGM) is larger, with a market capitalization of $143.56M compared with $118.91M for Inovio Pharmaceuticals (INO).
Which stock has performed better over the past year, BGM or INO?
INO returned -57.42% over the past 12 months, compared with -96.64% for BGM (price return, excluding dividends). Past performance does not predict future results.
Are BGM Group and Inovio Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.